Rhumbline Advisers Purchases 10,724 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Rhumbline Advisers increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 6.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 188,598 shares of the biopharmaceutical company’s stock after acquiring an additional 10,724 shares during the period. Rhumbline Advisers owned about 0.10% of Arbutus Biopharma worth $617,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ABUS. Creative Planning boosted its stake in shares of Arbutus Biopharma by 13.8% during the third quarter. Creative Planning now owns 49,500 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 5,989 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Arbutus Biopharma during the 3rd quarter worth approximately $142,000. Charles Schwab Investment Management Inc. grew its holdings in Arbutus Biopharma by 218.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after acquiring an additional 831,663 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Arbutus Biopharma by 453.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 30,723 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Arbutus Biopharma during the third quarter valued at $754,000. Institutional investors and hedge funds own 43.79% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ABUS. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $5.00 price target (up previously from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Trading Down 1.8 %

Shares of ABUS opened at $3.31 on Friday. The firm’s fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $3.64. Arbutus Biopharma Co. has a 12 month low of $2.30 and a 12 month high of $4.73. The stock has a market capitalization of $627.22 million, a P/E ratio of -7.70 and a beta of 1.93.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.